Insights into the role of genetic alterations in adrenocortical tumorigenesis

Molecular and Cellular Endocrinology

Volumn 300, Issue 1-2, 2009, Pages 169-174

  Herbet, M ^a,b   Feige, J J ^a,b   Thomas, M ^a,b  

^a INSERM   (France)

^b CEA GRENOBLE   (France)

Author keywords

Adenomas; Adrenal cortex; Carcinomas; Multistage tumorigenesis; Xenotransplantation

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1C; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; MITOTANE; PROTEIN P53; RNA H19; SOMATOMEDIN B; VASCULOTROPIN; WNT PROTEIN;

ADRENAL CORTEX; ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ALBRIGHT SYNDROME; ANGIOGENESIS; AUTOSOMAL DOMINANT DISORDER; BECKWITH WIEDEMANN SYNDROME; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CARNEY COMPLEX; CELL CYCLE REGULATION; CELL DAMAGE; CELL TRANSPLANTATION; CHROMOSOME 11P; DNA DAMAGE; ENDOCRINE TUMOR; FAMILIAL CANCER; FAMILIAL DISEASE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENETIC EPIGENESIS; GENETIC VARIABILITY; GERM LINE GENE THERAPY; MOLECULAR GENETICS; MUTATION; NONHUMAN; ONCOGENE RAS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; SURVIVAL RATE;

EID: 59649123557     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.10.010     Document Type: Review

References (64)

1. Allolio B., and Fassnacht M. Adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 91 (2006) 2027-2037
2. Angeli A., Osella G., Ali A., and Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm. Res. 47 (1997) 279-283
3. Bernard M.H., Sidhu S., Berger N., Peix J.L., Marsh D.J., Robinson B.G., Gaston V., Le Bouc Y., and Gicquel C. A case report in favor of a multistep adrenocortical tumorigenesis. J. Clin. Endocrinol. Metab. 88 (2003) 998-1001
4. Bernini G.P., Moretti A., Bonadio A.G., Menicagli M., Viacava P., Naccarato A.G., Iacconi P., Miccoli P., and Salvetti A. Angiogenesis in human normal and pathologic adrenal cortex. J. Clin. Endocrinol. Metab. 87 (2002) 4961-4965
5. Bertherat J., Groussin L., Sandrini F., Matyakhina L., Bei T., Stergiopoulos S., Papageorgiou T., Bourdeau I., Kirschner L.S., Vincent-Dejean C., Perlemoine K., Gicquel C., Bertagna X., and Stratakis C.A. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res. 63 (2003) 5308-5319
6. Beuschlein F., Reincke M., Karl M., Travis W.D., Jaursch-Hancke C., Abdelhamid S., Chrousos G.P., and Allolio B. Clonal composition of human adrenocortical neoplasms. Cancer Res. 54 (1994) 4927-4932
7. Blanes A., and Diaz-Cano S.J. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions. Hum. Pathol. 37 (2006) 1295-1303
8. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
9. Bourcigaux N., Gaston V., Logie A., Bertagna X., Le Bouc Y., and Gicquel C. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 85 (2000) 322-330
10. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 127 (2006) 469-480
11. Crucitti F., Bellantone R., Ferrante A., Boscherini M., and Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119 (1996) 161-170
12. de Fraipont F., El Atifi M., Gicquel C., Bertagna X., Chambaz E.M., and Feige J.J. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab. 85 (2000) 4734-4741
13. DePinho R.A. The age of cancer. Nature 408 (2000) 248-254
14. Eccles S.A., Box G., Court W., Sandle J., and Dean C.J. Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell. Biophys. 24 25 (1994) 279-291
15. Else T., Giordano T.J., and Hammer G.D. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 93 (2008) 1442-1449
16. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer. Biol. 3 (1992) 65-71
17. Gaujoux S., Tissier F., Groussin L., Libé R., Ragazzon B., Launay P., Audebourg A., Dousset B., Bertagna X., and Bertherat J. Wnt/beta-catenin and cAMP/PKA signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J. Clin. Endocrinol. Metab. 93 (2008) 4135-4140
18. Gicquel C., Bertagna X., Schneid H., Francillard-Leblond M., Luton J.P., Girard F., and Le Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 78 (1994) 1444-1453
19. Gicquel C., Leblond-Francillard M., Bertagna X., Louvel A., Chapuis Y., Luton J.P., Girard F., and Le Bouc Y. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin. Endocrinol. (Oxf). 40 (1994) 465-477
20. Gicquel C., Raffin-Sanson M.L., Gaston V., Bertagna X., Plouin P.F., Schlumberger M., Louvel A., Luton J.P., and Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 82 (1997) 2559-2565
21. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., Bertherat J., Chapuis Y., Duclos J.M., Schlumberger M., Plouin P.F., Luton J.P., and Le Bouc Y. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 61 (2001) 6762-6767
22. Giles R.H., van Es J.H., and Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653 (2003) 1-24
23. Grumbach M.M., Biller B.M., Braunstein G.D., Campbell K.K., Carney J.A., Godley P.A., Harris E.L., Lee J.K., Oertel Y.C., Posner M.C., Schlechte J.A., and Wieand H.S. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann. Int. Med. 138 (2003) 424-429
24. Henry I., Jeanpierre M., Couillin P., Barichard F., Serre J.L., Journel H., Lamouroux A., Turleau C., de Grouchy J., and Junien C. Molecular definition of the 11p15 5 region involved in Beckwith-Wiedemann syndrome and probably in predisposition to adrenocortical carcinoma. Hum. Genet. 81 (1989) 273-277
25. Hertel N.T., Carlsen N., Kerndrup G., Pedersen I.L., Clausen N., Hahnemann J.M., and Jacobsen B.B. Late relapse of adrenocortical carcinoma in Beckwith-Wiedemann syndrome. Clinical, endocrinological and genetic aspects. Acta Paediatr. 92 (2003) 439-443
26. Hirano Y., Fujita K., Suzuki K., Ushiyama T., Ohtawara Y., and Tsuda F. Telomerase activity as an indicator of potentially malignant adrenal tumors. Cancer 83 (1998) 772-776
27. Hisada M., Garber J.E., Fung C.Y., Fraumeni Jr. J.F., and Li F.P. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst. 90 (1998) 606-611
28. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
29. Icard P., Goudet P., Charpenay C., Andreassian B., Carnaille B., Chapuis Y., Cougard P., Henry J.F., and Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J. Surg. 25 (2001) 891-897
30. Ilvesmaki V., Kahri A.I., Miettinen P.J., and Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 77 (1993) 852-858
31. Kamio T., Shigematsu K., Sou H., Kawai K., and Tsuchiyama H. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum. Pathol. 21 (1990) 277-282
32. Kirschner L.S. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J. Clin. Endocrinol. Metab. 91 (2006) 14-21
33. Kolomecki K., Stepien H., Bartos M., and Kuzdak K. Usefulness of VEGF, MMP-2 MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr. Regul. 35 (2001) 9-16
34. Kopf D., Goretzki P.E., and Lehnert H. Clinical management of malignant adrenal tumors. J. Cancer Res. Clin. Oncol. 127 (2001) 143-155
35. Kozik A., Bradbury E.M., and Zalensky A. Increased telomere size in sperm cells of mammals with long terminal (TTAGGG)n arrays. Mol. Reprod. Dev. 51 (1998) 98-104
36. Lam W.W., Hatada I., Ohishi S., Mukai T., Joyce J.A., Cole T.R., Donnai D., Reik W., Schofield P.N., and Maher E.R. Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J. Med. Genet. 36 (1999) 518-523
37. Latronico A.C., and Chrousos G.P. Extensive personal experience: adrenocortical tumors. J. Clin. Endocrinol. Metab. 82 (1997) 1317-1324
38. Libé R., Groussin L., Tissier F., Elie C., Rene-Corail F., Fratticci A., Jullian E., Beck-Peccoz P., Bertagna X., Gicquel C., and Bertherat J. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin. Cancer Res. 13 (2007) 844-850
39. Maher E.R., and Reik W. Beckwith-Wiedemann syndrome: imprinting in clusters revisited. J. Clin. Invest. 105 (2000) 247-252
40. Mannelli M., Gelmini S., Arnaldi G., Becherini L., Bemporad D., Crescioli C., Pazzagli M., Mantero F., Serio M., and Orlando C. Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. J. Clin. Endocrinol. Metab. 85 (2000) 468-470
41. Mazzuco T.L., Chabre O., Feige J.J., and Thomas M. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing's syndrome features. J. Clin. Endocrinol. Metab. 91 (2006) 196-203
42. Mazzuco T.L., Chabre O., Sturm N., Feige J.J., and Thomas M. Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model. Endocrinology 147 (2006) 782-790
43. Moul J.W., Bishoff J.T., Theune S.M., and Chang E.H. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J. Urol. 149 (1993) 1389-1394
44. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 (1976) 23-28
45. Ocker M., Sachse R., Rico A., and Hensen J. PCR-SSCP analysis of human adrenocortical adenomas: absence of K-ras gene mutations. Exp. Clin. Endocrinol. Diabet. 108 (2000) 513-514
46. Ohgaki H., Kleihues P., and Heitz P.U. p53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 54 (1993) 408-410
47. Reincke M., Karl M., Travis W.H., Mastorakos G., Allolio B., Linehan H.M., and Chrousos G.P. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 78 (1994) 790-794
48. Sasano H., Suzuki T., Shizawa S., Kato K., and Nagura H. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod. Pathol. 7 (1994) 741-746
49. Schulte K.M., Heinze M., Mengel M., Scheuring S., Kohrer K., and Roher H.D. Complete sequencing and mRNA expression analysis of the MEN-I gene in adrenal myelolipoma. Horm. Metab. Res. 32 (2000) 169-173
50. Shao C., Deng L., Henegariu O., Liang L., Stambrook P.J., and Tischfield J.A. Chromosome instability contributes to loss of heterozygosity in mice lacking p53. Proc. Natl. Acad. Sci. USA 97 (2000) 7405-7410
51. Shen W.T., Sturgeon C., and Duh Q.Y. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J. Surg. Oncol. 89 (2005) 186-192
52. Shields J.M., Pruitt K., McFall A., Shaub A., and Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell. Biol. 10 (2000) 147-154
53. Sun B., Huang Q., Liu S., Chen M., Hawks C.L., Wang L., Zhang C., and Hornsby P.J. Progressive loss of malignant behavior in telomerase-negative tumorigenic adrenocortical cells and restoration of tumorigenicity by human telomerase reverse transcriptase. Cancer Res. 64 (2004) 6144-6151
54. Tadjine M., Lampron A., Ouadi L., Horvath A., Stratakis C.A., and Bourdeau I. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease. Clin. Endocrinol. (Oxf). 69 (2008) 367-373
55. Thomas M., and Hornsby P.J. Transplantation of primary bovine adrenocortical cells into scid mice. Mol. Cell. Endocrinol. 153 (1999) 125-136
56. Thomas M., Northrup S.R., and Hornsby P.J. Adrenocortical tissue formed by transplantation of normal clones of bovine adrenocortical cells in scid mice replaces the essential functions of the animals' adrenal glands. Nat. Med. 3 (1997) 978-983
57. Thomas M., Yang L., and Hornsby P.J. Formation of functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase. Nat. Biotechnol. 18 (2000) 39-42
58. Thomas M., Suwa T., Yang L., Zhao L., Hawks C.L., and Hornsby P.J. Cooperation of hTERT SV40 T antigen and oncogenic Ras in tumorigenesis: a cell transplantation model using bovine adrenocortical cells. Neoplasia 4 (2002) 493-500
59. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagnere A.M., Rene-Corail F., Jullian E., Gicquel C., Bertagna X., Vacher-Lavenu M.C., Perret C., and Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65 (2005) 7622-7627
60. Vogelstein B., and Kinzler K.W. The multistep nature of cancer. Trends Genet. 9 (1993) 138-141
61. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
62. Wooten M.D., and King D.K. Adrenal cortical carcinoma epidemiology and treatment with mitotane and a review of the literature. Cancer 72 (1993) 3145-3155
63. Yashiro T., Hara H., Fulton N.C., Obara T., and Kaplan E.L. Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia. World J. Surg. 18 (1994) 451-460 (55-460; discussion)
64. Zucman-Rossi J., Jeannot E., Nhieu J.T., Scoazec J.Y., Guettier C., Rebouissou S., Bacq Y., Leteurtre E., Paradis V., Michalak S., Wendum D., Chiche L., Fabre M., Mellottee L., Laurent C., Partensky C., Castaing D., Zafrani E.S., Laurent-Puig P., Balabaud C., and Bioulac-Sage P. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43 (2006) 515-524